The gig economy is being driven by those who seek to cut costs; this begins and ends with their ability to wiggle out of being considered “employers” in any sense.
Some pharmaceutical companies are cutting deals with insurers to favor brand-name products over cheaper versions.
Physicians and Green Party activist/politicians Jill Stein and Margaret Flowers say the two leading Democratic presidential candidates have something in common: covering up the failures of the Affordable Care Act.
On issue after issue, Clinton proposes incremental solutions that take into account our political system as it is. Sanders proposes dramatic solutions that will only be possible when power is wrested from "big money" interests.
Another drug company has joined the likes of the recently exposed Turing Pharmaceuticals by jacking up prices of life-sustaining meds on extremely short notice. Remember this name: Valeant Pharmaceuticals International.
A serious conversation is under way in the United States on the subject of psychiatric drugs The debate consists of three fundamental issues: first, whether antidepressants actually treat depression; second, the vast, growing body of evidence that psychotropic medications (more).
In this installment of Brave New Films' "Senator Sanders Unfiltered," the independent federal legislator from Vermont points out what's becoming hard to dispute or ignore, however much other members of Congress might do both: Wall Street, along with the pharmaceutical and insurance industries, practically runs Washington.
The number of Americans who are exploring the concept of better living through antidepressant chemistry nearly doubled in the decade from 1996 to 2005, according to a study published in Archives of General Psychiatry -- and that was well before the economic meltdown.